104th Day Of Lockdown

Maharashtra2119871152629026 Tamil Nadu114978665711571 Delhi100823720883115 Gujarat36858263231967 Uttar Pradesh2770718761785 Telangana2390212703295 Karnataka234749849372 West Bengal2212614711757 Rajasthan2026315965459 Andhra Pradesh200198920239 Haryana1750413335276 Madhya Pradesh1528411579617 Bihar12140901497 Assam11737743414 Odisha9526648648 Jammu and Kashmir84295255132 Punjab64914494132 Kerala5623334128 Chhatisgarh3207257814 Uttarakhand3161258642 Jharkhand2815204520 Goa181310617 Tripura158012061 Manipur13897330 Himachal Pradesh107074610 Puducherry101148014 Nagaland5782280 Chandigarh4874016 Arunachal Pradesh269781 Mizoram191130 Sikkim125650 Meghalaya80431
Lifestyle Health and Wellbeing 10 Dec 2018 Scientists to test t ...

Scientists to test tailor-made vaccine tech to fight epidemics

REUTERS
Published Dec 10, 2018, 10:26 am IST
Updated Dec 10, 2018, 10:26 am IST
Vaccine platform is system that uses same basic components as backbone and can be adapted to immunise against different diseases.
There are several years of research and testing ahead, but technology could one day lead to rapid production of “single shot” vaccines against an emerging epidemic. (Photo: Pixabay)
 There are several years of research and testing ahead, but technology could one day lead to rapid production of “single shot” vaccines against an emerging epidemic. (Photo: Pixabay)

London: A global coalition set up to fight disease epidemics is investing up to $8.4 million to develop a synthetic vaccine system that could be tailor-made to fight multiple pathogens such as flu, Ebola, Marburg and Rabies.

The deal, between the Coalition for Epidemic Preparedness Innovations (CEPI) and a team of scientists at Britain’s Imperial College London is aimed at progressing a “vaccine platform” which uses synthetic self-amplifying RNA (saRNA).

 

A vaccine platform is a system that uses the same basic components as a backbone or framework, and can be adapted to immunise against different diseases by inserting new genetic sequences from, for example, the flu or Marburg or rabies virus.

“It could be very transformative. It would change the way people view how to make vaccines,” said Robin Shattock, a specialist in Mucosal Infection and Immunity who leads the Imperial team developing the system, known as RapidVac.

He said there are several years of research and testing ahead, but hopes the technology could one day lead to rapid production of “single shot” vaccines against an emerging epidemic, or of “cocktail” vaccines against several different infectious diseases.

The thinking behind the saRNA approach is to harness the body’s own cell machinery to make an antigen - in other words a foreign substance that induces an immune response - rather than injecting the antigen itself directly into the body.

 “The other advantage is that it’s very rapid to manufacture because it’s a synthetic process,” Shattock said in a telephone interview.

Infectious disease epidemics such as Ebola outbreaks in Africa or Zika spreading from Brazil, are sporadic, unpredictable and fast-moving. Yet developing vaccines to combat them can currently take up to 10 years or more.

CEPI, which was set up at the start of 2017, aims to dramatically speed up the development of vaccines against new and unknown diseases - collectively known as Disease X

 “We cannot predict where or when Disease X will strike, but by developing these kinds of innovative vaccine technologies we can be ready for it,” said Richard Hatchett, CEPI’s chief executive and a specialist in medical countermeasures.

Under this agreement deal, Shattock’s team will work with German firm BioNTech RNA Pharmaceuticals and use the RapidVac platform to produce vaccines against a flu virus, the Rabies virus, and Marburg virus.

They aim to start safety trials in animal models in the lab early in 2019 and move to early stage clinical trials in humans within two years.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT